The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Pfizer PFE0.34%increase; green up pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.

Pfizer had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle. So last year the company created a phone line ...